This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

RNA Leaders USA
RNA breakthroughs, Case Studies and Partnerships
September 23-25, 2026Hynes Convention Center
Book Now
Menu
Book

Weimin Wang, PhD
Founder & CEO at Sanegene Bio
Speaker

Profile

Dr. Weimin Wang is a pioneer of the oligonucleotide medicinal chemistry field, he held scientific leadership positions at Sirna Therapeutics (acquired by Merck in 2006), Merck, and Dicerna Pharmaceuticals (acquired by Novo Nordisk in 2022). Weimin was a key inventor of innovative RNAi delivery solutions including GalXC™ and GalXC-Plus™ technologies, and contributed to the development of impactful RNAi medicines including Rivfloza® for primary hyperoxaluria, xalnesiran for chronic HBV infection, and lepodisiran for cardiovascular disease.He holds a Ph.D. in Chemistry from Rutgers University and a B.S. from Peking University, and has authored over 70 scientific papers and patents.

Agenda Sessions

  • From Concept to Clinic: Best-in-Class RNAi Therapeutics for Obesity, Cardiometabolic, and Autoimmune Diseases Powered by LEAD™

    , 11:45am
    View Session

At this event

Prev
Next
Anders Näär
Professor of Metabolic Biology
UC Berkeley

See Weimin at RNA Leaders USA

Book Now